← Back to Search

Gene Therapy

AGT103-T for HIV/AIDS

Phase 1
Waitlist Available
Research Sponsored by American Gene Technologies International Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up days 1 to 180 post-infusion
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new treatment where a patient's own immune cells are modified to better fight HIV. It targets people with HIV who have their virus under control with medication.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~days 1 to 180 post-infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and days 1 to 180 post-infusion for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Assess the safety of AGT103-T in HIV+ participants with well-controlled viremia on antiretroviral therapy: adverse events

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Low Dose CohortExperimental Treatment1 Intervention
A single infusion of ≥1x10e8 and \<1x10e9 genetically modified T cells.
Group II: High Dose CohortExperimental Treatment1 Intervention
A single infusion of ≥1x10e9 and \<5x10e9 genetically modified T cells.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AGT103-T
2020
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

American Gene Technologies International Inc.Lead Sponsor
3 Previous Clinical Trials
38 Total Patients Enrolled
~1 spots leftby Dec 2025